Nicolas Denervaud

Senior Director
12+ years of experience in performance improvement, value creation, and transactions, both as consultant and operator
Serves clients across a range of industries with a deep specialization in the medical device and biopharma sectors
Former CTO of Corin Group, a Permira portfolio company
Geneva
@alvarezmarsal
LinkedIn
Copied!
Nicolas Denervaud is a Senior Director with Alvarez & Marsal Private Equity Performance Improvement in Geneva. He has more than 12 years of experience in strategy execution, value creation, and transactions. Mr. Denervaud has worked with clients in various industries and has a deep specialization in the biopharma and medical device sectors. 

Notably at A&M, Mr. Denervaud led operational due diligence for a medical device company and a business in clinical food and supplements. He also supported a global life sciences consulting firm with the detailed design of a target operating model, including organizational design, process mapping, and governance review. Mr. Denervaud acted as Interim Chief Transformation Officer to ensure rapid and effective launch of the transformation program. 

Mr. Denervaud oversaw the merger of two medical device contract development and manufacturing organizations (CDMOs) with a joint global footprint of 13 production sites and a global supply chain. He ensured Day-1 readiness and drove the integration program spanning 12 workstreams, including designing a joint target operating model, assessing and realizing synergies (people, procurement, and cross-selling), and defining an optimized production site footprint. 

Mr. Denervaud’s other notable engagements include the assessment and pivot to execution of a cost savings program for a French network of medical diagnostics laboratories, due diligence of a pharmaceutical CDMO with more than 10 production sites in Europe and the US, and due diligence of a pharmaceutical CDMO with production in the UK. 

Prior to joining A&M, Mr. Denervaud served as Chief Transformation Officer at Corin Group, a global medical device company. He drove execution of a total value creation plan, including integrations and organizational restructuring, commercial operations improvement, and portfolio rationalization. As interim COO, he managed day-to-day operations, including suppliers, global distribution and logistics, manufacturing in the UK, and local customer operations in more than 10 countries. Before that, he held positions in strategy execution, leading operational and commercial transformation initiatives at Merck Group and Medtronic. He started his career at Boston Consulting Group. 

Mr. Denervaud earned a master’s degree in life sciences and technology and a PhD in bioengineering from EPFL (the Swiss Federal Institute of Technology in Lausanne). He is fluent in French and English. 

Latest insights The latest insights from Nicolas Denervaud's team
Thought Leadership
AI adoption has reached near-universal levels in engineering, yet a clear gap between perception and measured impact. This paper describes what those practices look like, why they matter, and how organizations can realize real value with AI-assisted engineering.